FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Summary by AI BETAClose X
Blood Cancer United, Inc., through its subsidiary TAP BCU Faron, LLC, has notified Faron Pharmaceuticals Ltd of a decrease in its holdings, resulting in a 3.47% stake in voting rights, representing 7,037,426 shares. This notification was made on May 14, 2026, following the threshold crossing on April 15, 2026. The company clarified that this percentage includes treasury shares, and would be 3.527% if treasury shares were excluded.
Faron Pharmaceuticals Ltd | Company announcement | May 18, 2026 at 09:00:00 EEST
TR-1: Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: | Faron Pharmaceuticals Ltd | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | X | |||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify) iii: Decrease of holdings | ||||||
| 3. Details of person subject to the notification obligation iv | ||||||
| Name | Blood Cancer United, Inc. | |||||
| City and country of registered office (if applicable) | Washington, D.C., United States of America | |||||
| 4. Full name of shareholder(s) (if different from 3.) v | ||||||
| Name TAP BCU Faron, LLC | ||||||
| City and country of registered office (if applicable) | Newark, Delaware, United States of America | |||||
| 5. Date on which the threshold was crossed or reached vi: | 15/04/2026 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 14/05/2026 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
| Resulting situation on the date on which threshold was crossed or reached | 3.47% | 3.47% | 7,037,426 | |||
| Position of previous notification (if applicable) | ||||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | |||||||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
| FI4000153309 | 7,037,426 | 3.47% | |||||||
| SUBTOTAL 8. A | 7,037,426 | 3.47% | |||||||
| B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Physical or cash Settlement xii | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | |||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | ||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv | X | |||
| Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| Blood Cancer United, Inc. 100% owner of TAP BCU, LLC | 0% | 0% | ||
| TAP BCU, LLC. 100% owner of TAP BCU Faron, LLC | 0% | 0% | ||
| TAP BCU Faron, LLC, | 3.47% | 3.47% | ||
| 10. In case of proxy voting, please identify: | ||||
| Name of the proxy holder | ||||
| The number and % of voting rights held | ||||
| The date until which the voting rights will be held | ||||
| 11. Additional information xvi | ||||
| Providing information directly to the Company as a result of meeting the threshold in the Company’s Arti-cles of Association (does not meet the AIM regulatory notification threshold). Gordon G. Miller, Jr. (“JR Miller”), Executive Vice President & Chief Financial Officer Blood Cancer United, Inc. and authorized controlling person with respect to: Blood Cancer United, Inc., TAP BCU, LLC and TAP BCU Faron, LLC TAP BCU Faron, LLC, c/o Blood Cancer United, Inc. 1201 15th Street N.W., Suite 410, Washington, D.C. 20005 U.S.A. +1.860.488.1774 Jr.Miller@bloodcancerunited.org 3.47% of shares and voting rights is as per Faron Pharmaceuticals Ltd. request to include Treasury Shares in the denominator. The percentage is 3.527% if exclude Treasury Shares. | ||||
| Place of completion | Blood Cancer United, Inc. Washington, D.C. U.S.A. |
| Date of completion | 14/05/2026 |
Latest directors dealings
- 2 hours ago Tertiary Minerals
- 2 hours ago Hargreaves Services
- 15 hours ago ASOS
- 16 hours ago MJ Gleeson
- 16 hours ago Rolls-Royce Holdings